Search

everythinglearnresearchcommunity

for

Search:↓

Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.

User shared progress pictures of hair regrowth on the crown/vertex after a transplant and using finasteride, Minoxidil foam, and a dermapen. They hope to fully regrow or increase density in the crown area.

A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.

The user is considering lowering the dosage of finasteride and minoxidil due to side effects like mood changes, lower libido, and brain fog, while wanting to maintain hair regrowth. A suggestion was made to try a lower dose of finasteride, such as 0.2 mg.

The user is seeking opinions on whether their hairline changes indicate regrowth or hair loss, using treatments like Rogaine, finasteride, microneedling, and Nizoral. They mention inconsistent finasteride use, scalp massages, and lifestyle factors like caffeine, nicotine, stress, and high sugar intake.

HairClone received grant money to start work after crowdfunding failed. They aim to offer treatments in early 2021, pending UK FDA licensing.

A user started applying 25mg RU58841 daily for hair regrowth and is considering increasing the dosage. They are seeking advice on effective dosages from others who have experienced regrowth with RU58841.

Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

The conversation discusses whether topical finasteride, dutasteride, or antiandrogens like RU58841 can reduce sebum overproduction as an early indicator of their effectiveness in treating hair loss. It suggests that while hair growth may take months to observe, a decrease in oiliness could be a quicker sign of a product's action.